Drug intelligence / Profile preview

VIR-8190

Development stage: Preclinical
Lead developer: Vir Biotechnology
Modality: IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

VIR-8190 is an investigational dual specificity human IgG1 monoclonal antibody that potently neutralizes both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) strains. These viruses are significant causes of lower respiratory tract disease, particularly in high-risk populations such as infants and immunocompromised individuals. VIR-8190 was identified using Vir Biotechnology’s proprietary monoclonal antibody discovery platform and targets the F, Fusion glycoprotein F0, a key viral protein involved in viral entry[1][2][3][6][8][10].

Targets

RSV F (Respiratory syncytial virus fusion protein)HMPV F (Human metapneumovirus fusion protein)

Beyond the preview

Go deeper on VIR-8190.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIR-8190.

Explore the full profile